The FDA is increasingly looking for quality issues across entire systems instead of isolated errors. A single unfavorable FDA 483 observation can now cost a company between $250,000 and $5 million in remediation, with more complex cases climbing much higher.
Manufacturing processes have become complex, multi-stage systems where a small deviation can quickly lead to batch failure. Traditional automation and standalone point solutions are no longer sufficient. While they handle individual tasks well, they do not manage the dependencies between quality, compliance, and production in real time.
To address this, the industry is shifting toward Multi-Agent Systems (MAS). These systems coordinate processes in real time, spotting issues early and keeping production and compliance under control before problems become cost-intensive.